Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit — 2nd Update
Novartis AG ADR NVS
News
Novartis Stops Late-Stage Trial for Key Drug in Rare Neuromuscular Disease
Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit — Update
Novartis Raises Guidance After Trial Setbacks Hit Profit
Novartis U.S. Shares Fall After MS Pill Trial Data Disappoint
Novartis Says MS Pill Helped Control Disease With Favorable Safety Data in Trials
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — Update
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
European Pharma Leaders Push for National Reforms to Boost Investment
Novartis to End ALS Trial Amid String of Study Failures
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
Novartis Down Over 12%, On Pace for Record Percent Decrease — Data Talk
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
Why the Dow is being dragged down by a Swiss company's bad news
Novartis's Latest Trial Setback Sinks Stock
United States